Intravenous tissue plasminogen activator (t-PA) is currently approved by the US Food and Drug Administration (FDA) for the treatment of ischemic stroke in patients > 18 years of age who present within 3 hours of stroke onset and meet certain criteria. We report a case of a 16-year-old, previously healthy female who presented with a basilar artery occlusion and pontine ischemic stroke. She was treated with intravenous t-PA approximately 4 hours after the onset of symptoms. The patient demonstrated a remarkable recovery 6 hours after onset of her symptoms and had minimal deficits on discharge from the hospital 1 week later. She was found to have a lupus anticoagulant and was heterozygous for the prothrombin gene G2010A mutation. These were likely contributing causes for her stroke. She was also homozygous for plasminogen activator inhibitor 1 (PAI-1) 4G/4G, which at present is a controversial stroke risk factor.
Kleindorfer D., Khoury J., Kissela B., et al. Temporal trends in the incidence and case fatality of stroke in children and adolescents. J Child Neurol. 2006;21:415-418.
2.
Janjua N., Nasar A., Lynch J., Qureshi AIThrombolysis for ischemic stroke in children. Stroke. 2007;38:1850-1854.
3.
Kleindorfer D., Broderick J., Khoury J., et al. The unchanging incidence and case-fatality of stroke in the 1990s: a population based study. Stroke. 2006;37:2473-2478.
4.
Kleindorfer D., Schneider A., Kissela B., et al. The effect of race and gender on patterns of rt-tPA use within a population. J Stroke Cerebrovasc Dis . 2003;12:217-220.
5.
Reeves M., Broderick J., Frankel M., et al. The Paul Coverdell National Acute Stroke Registry: initial results from four prototypes. Am J Prev Med. 2006;31(6 Suppl 2):S202-S209.
6.
Kuhle S., Mitchell L., Andrew M., et al. Urgent clinical challenges in children with ischemic stroke: Analysis of 1065 patients from the 1-800-NOCLOTS pediatric stroke telephone consultation service. Stroke. 2006;37:116-122.
7.
Gabis L., Yangala R., Lenn N.Time lag to diagnosis of stroke in children. Pediatrics. 2002;110:924-928.
8.
Wagner J., Lutsep H.Thrombolysis in Young Adults. J Thromb Thrombolysis. 2005;20:133-136.
9.
Braun KP, Kappelle LJ, Kirkham FJ, Deveber G.Diagnostic pitfalls in paediatric ischaemic stroke. Dev Med Child Neurol. 2006;48:985-990.
10.
Molofsky W.Managing Stroke in Children. Pediatr Ann. 2006;35:379-384.
11.
Zimmer JA, Garg BP, Williams LS, Golomb MRAge-related variation in presenting signs of childhood arterial ischemic stroke . Pediatr Neurol. 2007;37:171-175.
12.
Agrawal A., Joharapurkar S., Gharde P.Ischemic stroke in a child mistaken as functional disorder. Clin Neurol Neurosurg. 2007;109:876-879.
13.
Gokben S., Tosun A., Bayram N., et al. Arterial ischemic stroke in childhood: risk factors and outcome in old versus new era. J Child Neurol. 2007 ;22:1204-1208.
14.
Seligsohn U. , Lubetsky A.Genetic susceptibility to venous thrombosis . N Eng J Med. 2001;344:1222-1230.
15.
Casas JP, Hingorani AD, Bautista LE, Sharma P.Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch Neurol . 2004;61:1652-1661.
16.
Bonduel M., Sciuccati G., Hepner M., et al. Factor V Leiden and prothrombin gene G20210A mutation in children with cerebral thromboembolism. Am J Hematol. 2003;73:81-86.
17.
Nowak-Gottl U., Strater R., Kosch A., et al. The plasminogen activator inhibitor (PAI)-1 promoter 4G/4G genotype is not associated with ischemic stroke in a population of German children. Eur J Haematol. 2001;66:57-62.
18.
Tsantes A., Nikopoulos G., Bagos P., et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of ischemic stroke: a meta-analysis. Blood Coagul Fibrinolysis . 2007;18:497-504.
19.
Kenet G., Sadetzki S., Murad H., et al. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke. 2000;31:1283-1288.
20.
Kamat A., D'Cruz D., Hunt B.Managing antiphospholipid antibodies and antiphospholipid syndrome in children . Haematologica. 2006;91:1674-1680.
21.
Miyakis S., Lockshin M., Atsumi T., et al. International consensus statement on an update of the definite classification criteria for antiphospholipid syndrome. J Thromb Haemostasis. 2006;4:295-306.
22.
Muscal E., Brey R.Neurological manifestations of the antiphospholipid syndrome: risk assessments and evidence-based medicine. Int J Clin Pract. 2007;61:1561-1568.
23.
Avcin T., Toplak N.Antiphospholipid antibodies in response to infection. Curr Rheumatol Rep. 2007;9:212-218.
24.
Chiarantini E., Valanzano R., Liotta A., et al. Hemostatic abnormalities in inflammatory bowel disease. Thromb Res. 1996;82: 137-146.
25.
Adams H., Adams R., Brott T., et al. Guidelines for the early management of patients with ischemic stroke. Stroke. 2003;34: 1056-1083.
26.
Voetsch B., DeWitt LD, Pessin MS, Caplan LRBasilar artery occlusive disease in the New England Medical Center Posterior Circulation Registry. Arch Neurol. 2004;61:496-504.
27.
Glass T., Hennessy P., Pazdera L., et al. Outcome at 30 days in the New England Medical Center Posterior Circulation Registry. Arch Neurol. 2002;59:369-376.
28.
Hacke W., Donnan G., Fieschi C., et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet . 2004;363:768-774.
